Later studies increased complexity by modeling tumor angiogenesis to examine the effect of the tumor microenvironment on anti-VEGF treatment efficacy [71], [72], and included targeting specific VEGF isoforms [73]. This evidence concerns the gene VEGFA and neoplasm.